Dexcel Pharma Technologies SC 13G Protalix BioTherapeutics / Dexcel Pharma Technologies ownership change

Exhibit 99.1

JOINT FILING AGREEMENT

PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows that such information is inaccurate.

Dated: March 25, 2020.

/s/ Dan Oren

Dan Oren

DEXCEL PHARMA TECHNOLOGIES LTD.
By:	/s/ Dan Oren
	Name: Dan Oren
	Title: Executive Chairman